Changes of plasma levels of sTRAIL and its DR4, DR5 in hypertension patients with left ventricular hypertrophy
10.3969/j.issn.1008-0074.2013.02
- VernacularTitle:高血压左室肥厚患者血浆sTRAIL、sDR4、sDR5水平的变化
- Author:
Yan HONG
;
Yanfang XIE
;
Yanting WAN
;
Lina WAN
;
Jianhua HU
- Publication Type:Journal Article
- Keywords:
Hypertension;
Hypertrophy, left ventricular;
Apoptosis
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2013;22(2):105-108
- CountryChina
- Language:English
-
Abstract:
Objective: To determine plasma levels of soluble tumor necrosis factor-related apoptosis inducing ligand (sTRAIL) and its soluble death receptor (sDR4, sDR5) in essential hypertension (EH) patients with left ventricular hypertrophy (LVH). Methods: Enzyme linked immunosorbent assay (ELISA) was used to measure plasma levels of sTRAIL, sDR4 and sDR5 in 50 EH + LVH patients (EH + LVH group), 50 EH patients without LVH (EH group) and 50 healthy subjects (healthy control group), and the results were compared and analyzed among three groups. Results: ① Compared with healthy control group and EH group, there were significant increase in plasma levels of sTRAIL [(0.95±0.11) ng/ml vs. (1.12±0.86) ng/ml vs. (1.74±1.19) ng/ml], sDR4[(2.38±0.32) pg/ml vs. (5.63±1.05) pg/ml vs. (8.72±1.14) pg/ml] and sDR5[(< 6 pg/ml) vs. (39.19±8.23) pg/ml vs. (78.21±11.2) pg/ml] in EH + LVH group, P<0.01 all; and levels of sDR4 and sDR5 in EH group were significantly higher than those of healthy control group (P<0.01 both), but there was no significant difference in sTRAIL level between the two groups (P>0.05); ② Pearson correlation analysis indicated that there were significant positive correlation among levels of sTRAIL, sDR4 and sDR5 in EH + LVH patients (r=0.325~0.410, P<0.05 or <0.01). Conclusion: Plasma levels of sTRAIL, sDR4 and sDR5 may be valuable indexes for prediction of left ventricular hypertrophy in patients with hypertension.
- Full text:P020130514414424686371.doc
